Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus acidophilus + lacticaseibacillus rhamnosus + bifidobacterium bifidum + bifidobacterium longum + enterococcus faecium + fructo-oligosaccharides + lactulose
- Development stage
- Unknown
- Lead developer
- Nobel İlaç
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This multispecies synbiotic is a live biotherapeutic product developed by Nobel Ilac and Cell Biotech Co. for the treatment of exogenous obesity in children and adolescents. The formulation consists of five probiotic strains—*Lactobacillus acidophilus*, *Lacticaseibacillus rhamnosus*, *Bifidobacterium bifidum*, *Bifidobacterium longum*, and *Enterococcus faecium*—at a total concentration of 2.5 x 10^9 CFU per sachet. These are combined with the prebiotics fructo-oligosaccharides (FOS) and lactulose, and enriched with a complex of vitamins (A, B1, B2, B6, C, and E). Administered orally, the product functions by modulating the gut microbiota composition, specifically decreasing the Firmicutes/Bacteroidetes ratio and increasing the relative abundance of beneficial genera such as *Prevotella* and *Dialister*. Clinical results from the Probesity-2 trial demonstrated that this synbiotic, as an adjunct to standard diet and exercise, leads to significant improvements in anthropometric measurements, including reductions in body weight, BMI, and waist circumference.
- Brand names
- NBL Probiotic Optima
- Other names
- Probesity-2 synbioticProbesity2 synbioticProbesity 2 synbioticmultispecies synbiotic
Beyond the preview
Go deeper on lactobacillus acidophilus + lacticaseibacillus rhamnosus + bifidobacterium bifidum + bifidobacterium longum + enterococcus faecium + fructo-oligosaccharides + lactulose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus acidophilus + lacticaseibacillus rhamnosus + bifidobacterium bifidum + bifidobacterium longum + enterococcus faecium + fructo-oligosaccharides + lactulose.